Showing posts with label Global Erythropoietin Drugs Market Company Profiles 2013-2020. Show all posts
Showing posts with label Global Erythropoietin Drugs Market Company Profiles 2013-2020. Show all posts

Friday, 6 February 2015

Global Erythropoietin Drugs Market - Size, Share, Global Trends, Company Profiles


Global Erythropoietin Drugs Market - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Forecast 2013-2020

Report Overview
Research Beam adds a report titled “Global Erythropoietin Drugs Market (Products, Applications and Geography) 2013-2020” that provides detailed information of the Global Erythropoietin Drugs Market. The report is an excellent piece of study for investors who are looking towards the market.

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others. The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. The global EPO drugs market would reach $11.9 billion by 2020, registering CAGR of 9.7% during 2014-2020.

Amongst all synthetic erythropoietin products, Epoetin alfa and its advance version, Darbepoetin alfa, are the most popular drugs. Epoetin alfa and Darbepoetin alfa collectively accounted for ~80% of total EPO drugs market revenue. Amgen Inc. was first company to innovate Epoetin alfa and Darbepoetin alfa that are branded/patented as Epogen and Aranesp respectively. However, expiration of Amgen’s patent for Epogen has aided manufacturers of biosimilars to enter the EPO drugs market. Availability of numerous biosimilars has rendered low-cost option to the patients, therefore increased adoption rates for EPO drugs particularly in the developing regions.

Table of Contents:

CHAPTER 1 INTRODUCTION
1.1  Key Benefits
1.2  Key Market Segments
1.3  Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Analyst tools and models


CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market beyond what to expect by 2025 ($Million)
2.1.1 Moderate growth scenario
2.1.2 Rapid growth scenario
2.1.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Evolution of Erythropoietin drugs
3.3 Erythropoietin Omega and Delta: pruned R&D pipeline drugs
3.4 Ethical considerations of erythropoietin drugs
3.5 Key findings
3.5.1 Top Factors Impacting for Global Erythropoietin Drugs Market
3.5.2 Top Investment Pockets for Global Erythropoietin Drugs Market
3.6 Value Chain Analysis

For More Information Kindly Contact:
Call Us :
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555

Or Mail Us :
Visit Our Blog :